Opaleye Management’s KALA BIO KALA Stock Holding History

Opaleye Management’s Portfolio KALA Stock Details KALA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-145	Closed	-$3.79M	–	63
2020 Q2	$3.79M	Sell	145 -168	-54%	-$4.76M	0.77%	35
2020 Q1	$7.23M	Buy	+313	New	+$5M	1.92%	18

Other funds holding KALA

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Opaleye Management's KALA Position: Q3 2020 in Review

Opaleye Management sold out of KALA BIO (KALA) in Q3 2020, closing a stake of 145 shares — an estimated $3.79M sold.

Opaleye Management first reported a position in KALA in Q1 2020 and held it in 2 quarters. The position peaked at $7.23M in Q1 2020. 105 funds tracked by Wall St. Rank hold KALA as of Q3 2020.

Opaleye Management reported no remaining KALA BIO position as of Q3 2020 after selling out during the quarter.
Opaleye Management sold 145 KALA BIO shares in Q3 2020, an estimated $3.79M.
Opaleye Management first reported a position in KALA BIO in Q1 2020 and held it in 2 quarters.
Opaleye Management's KALA BIO position peaked at $7.23M in Q1 2020.
105 funds tracked by Wall St. Rank held KALA BIO as of Q3 2020.

Based on Opaleye Management's 13F filing for Q3 2020, filed 16 Nov 2020.